Phase 2a Design The open-label, proof-of-concept, Phase 2a portion of the study was designed to evaluate the safety and efficacy of AG-946 in adults with anemia due to lower-risk MDS.

The mean (±SD) ALSFRS-R scores at week 24 (33.75 ±3.3) and week 48 (32 ±7.8) after initiation of treatment with COYA 302 were not statistically different compared to the ALSFRS-R score at ...

When controlling for net price, treatments with the highest BURDEN score had a 22.0–percentage point reduction in UM restrictions relative to those with low BURDEN score (P = .041).

Late-phase confirmatory Clinical Trials on the Horizon: With the successful proof of concept, Neuraptive Therapeutics, Inc. is now preparing to initiate late-phase human clinical trials for NTX-001.

JOINT BASE CHARLESTON, S.C. – Culminating with an in-flight demonstration on April 30, the Negatively Pressurized Conex (NPC) proof of concept prototype successfully proved its capability to ...

"Proof of concept of new material for long lasting relief from dry mouth conditions." ScienceDaily. ScienceDaily, 20 November 2023. <www.sciencedaily.com / releases / 2023 / 11 / 231120124132.htm>.